EpiCast Report: Acne - Epidemiology Forecast to 2022

NEW YORK, Sept. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Acne - Epidemiology Forecast to 2022

http://www.reportlinker.com/p01623034/EpiCast-Report-Acne---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

EpiCast Report: Acne - Epidemiology Forecast to 2022

Summary

GlobalData's epidemiological analysis forecasts an increase in the total prevalent cases of acne in people ages 10–44 years in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK), from 103.91 million prevalent cases in 2012 to 105.46 million prevalent cases in 2022, with a decadal growth rate of 1.5%. As GlobalData epidemiologists used steady prevalence proportions of acne over the forecast period, the growth in prevalent cases in each market can be attributed to the change in population demographics in people ages 10–44 years in the respective markets.

Although acne is not a life-endangering condition, it is associated with a huge psychosocial impact and economic burden. GlobalData's epidemiological forecast emphasizes the need for preventive measures that are directed towards high-risk groups and signifies the need for early intervention with the available effective treatments in order to tackle the increasing burden of acne.

GlobalData epidemiologists forecast the prevalent cases of acne in the 6MM from 2012–2022 using nationally-representative, country-specific studies published in peer-reviewed journals that provided the age- and sex-specific prevalence of acne in the 6MM. Additionally, they further segmented the total prevalent cases of acne by severity. GlobalData epidemiologists ensured that the forecast methodology was consistent across all the 6MM to allow for a meaningful comparison of the total prevalent cases of acne across these markets.

Scope

- The Acne EpiCast Report provides an overview of the risk factors and global trends of acne in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of acne prevalent cases segmented by age (in five-year increments beginning at age 0 and ending at age 44 years), sex, and stage in these six markets.- The acne epidemiology report is written and developed by Masters- and PhD-level epidemiologists.- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global acne market. - Quantify patient populations in the global acne market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for acne therapeutics in each of the markets covered. - Identify the percentage of acne prevalent cases by stage.1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 52 Introduction 62.1 Catalyst 63 Epidemiology 73.1 Disease Background 73.2 Risk Factors and Comorbidities 83.2.1 A family history of acne increases the risk of acne by four times 83.2.2 Diet is the most common aggravating factor of acne 93.2.3 The relationship between smoking and acne is unclear 103.2.4 Depression and anxiety are common comorbidities in acne patients 113.3 Global Trends 123.3.1 US 133.3.2 5EU 143.4 Forecast Methodology 163.4.1 Sources Used 173.4.2 Sources Not Used 203.5 Forecast Assumptions and Methods 213.5.1 US 213.5.2 France 223.5.3 Germany 223.5.4 Italy and Spain 233.5.5 UK 243.6 Epidemiology Forecast for Acne (2012–2022) 253.6.1 Total Prevalent Cases of Acne Vulgaris 253.6.2 Age-Specific Total Prevalent Cases of Acne Vulgaris 273.6.3 Sex-Specific Total Prevalent Cases of Acne Vulgaris 293.6.4 Age-Standardized Total Prevalence of Acne Vulgaris 313.6.5 Total Prevalent Cases of Acne Vulgaris by Severity 333.7 Discussion 353.7.1 Conclusions on Epidemiological Trends 353.7.2 Limitations of the Analysis 363.7.3 Strengths of the Analysis 374 Appendix 384.1 Bibliography 384.2 About the Authors 434.2.1 Epidemiologists 434.2.2 Reviewers 434.2.3 Global Director of Epidemiology and Health Policy 454.2.4 Global Head of Healthcare 454.3 About GlobalData 464.4 About EpiCast 464.5 Disclaimer 47

1.1 List of Tables

Table 2: Classification of Acne Severity 16

Table 3: 6MM, Sources of Acne Prevalence Data 17

Table 4: 6MM, Sources of Acne Severity Data 17

Table 5: 6MM, Total Prevalent Cases of Acne Vulgaris, Ages 10–44 years, Both Sexes, N (Millions), 2012–2022 26

Table 6: 6MM, Total Prevalent Cases of Acne Vulgaris, by Age, Both Sexes, N (Millions), (Row %), 2012 27

Table 7: 6MM, Total Prevalent Cases of Acne Vulgaris, by Sex, Ages 10–44 Years, N (Row %), 2012 29

Table 8: 6MM, Total Prevalent Cases of Acne Vulgaris by Severity, Ages 10–44 Years, Both Sexes, N (Millions) (Row %), 2012 33

1.2 List of Figures

Figure 1: 6MM, Total Prevalent Cases of Acne Vulgaris, Ages 10–44 years, Both Sexes, N (Millions), 2012–2022 26Figure 2: 6MM, Total Prevalent Cases of Acne Vulgaris, by Age, Both Sexes, N (Millions), 2012 28Figure 3: 6MM, Total Prevalent Cases of Acne Vulgaris, by Sex, Ages 10–44 Years, N (Millions), 2012 30Figure 4: 6MM, Age-Standardized Total Prevalence of Acne Vulgaris, Ages 10–44 Years, 2012 32Figure 5: 6MM, Total Prevalent Cases of Acne Vulgaris by Severity, Ages 10–44 Years, Both Sexes, N (Millions), 2012 34

To order this report: EpiCast Report: Acne - Epidemiology Forecast to 2022 http://www.reportlinker.com/p01623034/EpiCast-Report-Acne---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker